在转移性黑色素瘤中进行个性化,自身的新抗原特异性T细胞疗法:一期1试验
Jessica S W Borgers1, Divya Lenkala2, Victoria Kohler2
1Department of Medical Oncology, Netherlands Cancer Institute (NKI), Amsterdam, The Netherlands.
Nature medicine
|January 3, 2025
概括
这项研究介绍了BNT221,一种针对晚期黑色素瘤的个性化T细胞疗法. 该治疗证明了安全性,并诱导了新抗原特异性T细胞反应,显示出作为新疗法选择的前景.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 细胞疗法细胞疗法
背景情况:
- 晚期黑色素瘤往往对免疫检查点阻塞 (ICB) 和BRAF向治疗等标准治疗变得耐药.
- 对于耐治疗性晚期黑色素瘤患者来说,新的治疗策略至关重要.
研究的目的:
- 为了评估BNT221的安全性和初步抗瘤活性,BNT221是一种个性化的新抗原特异性T细胞产品.
- 确定最高耐受剂量 (HTD) 并确定在晚期黑色素瘤患者中进行进一步调查的推剂量.
主要方法:
- 在ICB和/或BRAF向治疗后进展的晚期黑色素瘤的9名患者中进行了一项1,3+3期剂量检测研究.
- 作为单疗法,BNT221用于两种剂量级 (DL1和DL2). 评估了安全性,剂量限制性毒性 (DLT) 和抗瘤反应.
- 探索性分析包括对T细胞反应的评估,血液和瘤中的新抗原特异性克隆类型,以及药物产品的产生.
主要成果:
- 在两种剂量水平中,BNT221耐受性良好,没有观察到与T细胞产品相关的3级或更高剂量限制毒性.
- 为了进一步研究,确定了一剂5.0 × 10^8 - 1.0 × 10^10细胞.
- 在9名患者中,有6名患者实现了稳定疾病作为最佳整体反应,在4名患者中观察到瘤减少. 新抗原特异性T细胞反应被生成并在治疗后检测到.
结论:
- 个性化的新抗原特异性采用性T细胞疗法BNT221在晚期黑色素瘤患者中显示出良好的安全性.
- 该研究为BNT221提供了概念证明,证明其产生功能性,新抗原特异性T细胞反应的能力,并表明潜在的临床活性.
相关概念视频
01:27Tumor Immunotherapy
472
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
472
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K